Global Preventative Medicine Demand And mRNA Pipelines Will Transform Healthcare

Published
11 Apr 25
Updated
06 Aug 25
AnalystHighTarget's Fair Value
US$121.78
79.1% undervalued intrinsic discount
06 Aug
US$25.47
Loading
1Y
-68.7%
7D
-7.9%

Author's Valuation

US$121.8

79.1% undervalued intrinsic discount

AnalystHighTarget Fair Value

Shared on07 May 25
Fair value Decreased 1.09%

Shared on30 Apr 25
Fair value Decreased 3.15%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25
Fair value Increased 43%

AnalystHighTarget has increased future PE multiple from 84.2x to 120.1x.

Shared on16 Apr 25
Fair value Decreased 0.66%

AnalystHighTarget made no meaningful changes to valuation assumptions.